Evidence map›Paper›PMID 37794717›Full record

ArticleACR open rheumatology2023

Economic and Health Care Resource Use Burden of Systemic Sclerosis.

Dinesh Khanna, Daniel E Furst, Justin W Li, Qian Meng, Yuan Yuan, Tamara Lesperance, Kenyatta Peoples, Farah Ali, Brian LaMoreaux, Stephanie D Taylor

Open access · goldAbstract read
In one paragraph

Article in ACR open rheumatology, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
0.5field-weighted citation impact, top 30% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 4 citations in OpenAlex.

  1. Article
  2. Review
  3. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 1 institution in 2 countries.

Dinesh KhannaUniversity of Michigan Medical Center, Ann Arbor.ORCID https://orcid.org/0000-0003-1412-4453
Daniel E FurstUniversity of California, Los Angeles, University of Florence, Florence, Italy, and University of Washington, Seattle.ORCID https://orcid.org/0000-0001-7857-2373
Justin W LiTrinity Life Sciences, Waltham, Massachusetts.
Qian MengTrinity Life Sciences, Waltham, Massachusetts.
Yuan YuanTrinity Life Sciences, Waltham, Massachusetts.
Tamara LesperanceHorizon Therapeutics, Deerfield, Illinois.
Kenyatta PeoplesHorizon Therapeutics, Deerfield, Illinois.
Farah AliHorizon Therapeutics, Deerfield, Illinois.
Brian LaMoreauxHorizon Therapeutics, Deerfield, Illinois.ORCID https://orcid.org/0000-0001-7521-241X
Stephanie D TaylorHorizon Therapeutics, Deerfield, Illinois.ORCID https://orcid.org/0000-0001-6222-3128
Trinity Health · US

Funding

Horizon Therapeutics N/A
6 · The paper itself

Abstract

objectiveTo describe the health care resource use (HCRU) and costs of patients with systemic sclerosis (SSc) prior to and after diagnosis.

methodsThis retrospective study used a claims data set (Merative MarketScan; 2015-2019). Eligible patients with SSc were identified by diagnosis codes and required at least 24 months of enrollment without an SSc diagnosis before their first SSc claim and at least 12 months of enrollment thereafter. Total HCRU and costs were reported for three intervals: 2 years and 1 year before and 1 year after index diagnosis. A general population cohort without SSc was matched 1:1 to the SSC cohort on age and sex for comparison.

resultsEligibility criteria identified 902 patients with SSc (mean age: 54 years old; 85% female). Mean per-member per year costs increased each year from $22,383 to $29,708 to $47,095, 2 years before, 1 year before, and 1 year after index diagnosis versus $10,232 to $9656 to $9714 in the general population cohort. Outpatient settings represented the largest proportion of cost 1 year after SSc diagnosis ($16,392), followed by prescription drugs ($10,692), physician office ($10,523), and inpatient ($9448) settings.

conclusionPatients with SSC accrued greater costs and required more services than a general population cohort. These elevated expenditures and HCRU were observed at least 2 years before an SSc diagnosis and increased over time, reflecting both the progressive, multisystem nature of SSc and potential challenges in diagnosis. These findings suggest that SSc poses a substantial burden on the US health care system and highlights the need for early diagnosis and effective therapies.

Identifiers

PMID37794717
PMCPMC10716802
OpenAlexW4387356990

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.